Exclusive: DeepMind CEO Demis Hassabis talks secretive new AI biotech Isomorphic Labsnews2023-09-26T14:34:04+00:00September 26th, 2023|Endpoints News|
Intercept to sell in $800M cash buyout after second NASH rejection sank hopesnews2023-09-26T14:09:33+00:00September 26th, 2023|Endpoints News|
Poxel takes writedown on NASH drug as it continues layoffs, search for cashnews2023-09-26T11:18:48+00:00September 26th, 2023|Endpoints News|
Ionis plans NDA for first wholly-owned drug after positive PhIII data in familial chylomicronemia syndromenews2023-09-26T11:13:35+00:00September 26th, 2023|Endpoints News|
Omega Therapeutics’ epigenomic medicines reduce MYC expression by 55% in early study of cancer patientsnews2023-09-26T11:00:55+00:00September 26th, 2023|Endpoints News|
Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic normsnews2023-09-26T10:40:27+00:00September 26th, 2023|Endpoints News|
Updated: Roivant’s FcRn antibody for autoimmune disease shows early potential in study with healthy subjectsnews2023-09-26T10:11:19+00:00September 26th, 2023|Endpoints News|
Acesion clinches $47M in Series B raise to advance preclinical cardiac arrhythmia candidate through PhIInews2023-09-26T07:47:58+00:00September 26th, 2023|Endpoints News|
Takeda strikes $500M+ deal for California biotech’s ALS programnews2023-09-25T19:50:02+00:00September 25th, 2023|Endpoints News|
FDA rejects Coherus’ reworked Neulasta biosimilar due to third-party inspectionsnews2023-09-25T18:48:33+00:00September 25th, 2023|Endpoints News|
